142 related articles for article (PubMed ID: 7736924)
1. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
Laurenzana EM; Sorrels SL; Owens SM
Drug Metab Dispos; 1995 Feb; 23(2):271-8. PubMed ID: 7736924
[TBL] [Abstract][Full Text] [Related]
2. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6.
Cribb A; Nuss C; Wang R
Drug Metab Dispos; 1995 Jul; 23(7):671-5. PubMed ID: 7587952
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
Jaruratanasirikul S; Cooper AD; Blaschke TF
Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
[TBL] [Abstract][Full Text] [Related]
4. Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody.
Nakamura A; Yamamoto Y; Tasaki T; Sugimoto C; Masuda M; Kazusaka A; Fujita S
Drug Metab Dispos; 1995 Nov; 23(11):1268-73. PubMed ID: 8591729
[TBL] [Abstract][Full Text] [Related]
5. Affinity and potency of proinhibitory antipeptide antibodies against CYP2D6 is enhanced using cyclic peptides as immunogens.
Schulz-Utermoehl T; Edwards RJ; Boobis AR
Drug Metab Dispos; 2000 May; 28(5):544-51. PubMed ID: 10772633
[TBL] [Abstract][Full Text] [Related]
6. Improved separation and immunodetection of rat cytochrome P450 4A forms in liver and kidney.
Okita JR; Johnson SB; Castle PJ; Dezellem SC; Okita RT
Drug Metab Dispos; 1997 Aug; 25(8):1008-12. PubMed ID: 9280410
[TBL] [Abstract][Full Text] [Related]
7. Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
Leeder JS; Gaedigk A; Lu X; Cook VA
Mol Pharmacol; 1996 Feb; 49(2):234-43. PubMed ID: 8632755
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a rat liver cytochrome P-450UT-H cDNA clone and comparison of mRNA levels with catalytic activity.
Churchill PF; Churchill SA; Martin MV; Guengerich FP
Mol Pharmacol; 1987 Feb; 31(2):152-8. PubMed ID: 3543648
[TBL] [Abstract][Full Text] [Related]
9. Two monoclonal antibodies recognizing different epitopes on rat cytochrome IIB1 react with human IIE1.
Wrighton SA; Vandenbranden M; Becker GW; Black SD; Thomas PE
Mol Pharmacol; 1992 Jan; 41(1):76-82. PubMed ID: 1370708
[TBL] [Abstract][Full Text] [Related]
10. A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning, and enzyme characterization.
Sakamoto K; Kirita S; Baba T; Nakamura Y; Yamazoe Y; Kato R; Takanaka A; Matsubara T
Arch Biochem Biophys; 1995 Jun; 319(2):372-82. PubMed ID: 7786018
[TBL] [Abstract][Full Text] [Related]
11. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
12. Production of a form-specific, inhibitory antibody against rat cytochrome P450 2B1 using a synthetic peptide antigen against a putative substrate binding site.
Charnecki J; Putt D; Kim EY; Kim H
Biochem Biophys Res Commun; 1995 Nov; 216(3):1024-33. PubMed ID: 7488175
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D
Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124
[TBL] [Abstract][Full Text] [Related]
14. Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats.
Cooper KO; Reik LM; Jayyosi Z; Bandiera S; Kelley M; Ryan DE; Daniel R; McCluskey SA; Levin W; Thomas PE
Arch Biochem Biophys; 1993 Mar; 301(2):345-54. PubMed ID: 7681660
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
16. Differences in cytochrome P450-mediated biotransformation of 1,2-dichlorobenzene by rat and man: implications for human risk assessment.
Hissink AM; Oudshoorn MJ; Van Ommen B; Haenen GR; Van Bladeren PJ
Chem Res Toxicol; 1996 Dec; 9(8):1249-56. PubMed ID: 8951226
[TBL] [Abstract][Full Text] [Related]
17. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides.
Boundy VA; Luedtke RR; Artymyshyn RP; Filtz TM; Molinoff PB
Mol Pharmacol; 1993 May; 43(5):666-76. PubMed ID: 8502224
[TBL] [Abstract][Full Text] [Related]
18. Anti-peptide antibodies to the P4502D subfamily in rat, dog and man.
Nakamura A; Yamamoto Y; Tasaki T; Sugimoto C; Masuda M; Kazusaka A; Fujita S
Xenobiotica; 1995 Nov; 25(10):1103-9. PubMed ID: 8578766
[TBL] [Abstract][Full Text] [Related]
19. Purification from liver microsomes from untreated cynomolgus monkeys of cytochrome P450 closely related to human cytochrome P450 2B6.
Ohmori S; Shirakawa C; Motohashi K; Yoshida H; Abe H; Nakamura T; Horie T; Kitagawa H; Asaoka K; Rikihisa T
Mol Pharmacol; 1993 Feb; 43(2):183-90. PubMed ID: 8429823
[TBL] [Abstract][Full Text] [Related]
20. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1).
Yamamoto AM; Cresteil D; Boniface O; Clerc FF; Alvarez F
Eur J Immunol; 1993 May; 23(5):1105-11. PubMed ID: 7682958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
